Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research note published on Monday,Benzinga reports. The firm currently has a $13.00 price target on the stock.

Several other research analysts have also recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a research report on Friday. Morgan Stanley downgraded shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th.

Immuneering Stock Down 3.3 %

Shares of Immuneering stock opened at $1.74 on Monday. The firm has a market cap of $54.03 million, a price-to-earnings ratio of -0.88 and a beta of -0.32. Immuneering has a 52-week low of $1.00 and a 52-week high of $3.83. The company’s 50-day simple moving average is $1.79 and its 200-day simple moving average is $2.00.

Immuneering (NASDAQ:IMRX) last released its earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16). Equities research analysts anticipate that Immuneering will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Immuneering

Several institutional investors and hedge funds have recently made changes to their positions in the business. HighTower Advisors LLC increased its holdings in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after acquiring an additional 9,400 shares in the last quarter. Corsair Capital Management L.P. purchased a new position in shares of Immuneering during the 3rd quarter worth approximately $25,000. Two Sigma Investments LP raised its position in shares of Immuneering by 25.0% during the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after purchasing an additional 10,126 shares during the last quarter. Tang Capital Management LLC purchased a new stake in Immuneering in the 4th quarter valued at approximately $27,000. Finally, Southport Management L.L.C. grew its holdings in Immuneering by 4.9% during the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after buying an additional 10,000 shares during the last quarter. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.